

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Aug-2023  
Document Type: USP Monographs  
DocId: GUID-0FF697DF-A945-4F14-997C-EFD080C792EF\_4\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M54777\\_04\\_01](https://doi.org/10.31003/USPNF_M54777_04_01)  
DOI Ref: 5bha5

© 2025 USPC  
Do not distribute

# Montelukast Sodium Tablets

**DEFINITION**

Montelukast Sodium Tablets contain Montelukast Sodium equivalent to NLT 92.5% and NMT 107.5% of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ).

[NOTE—Avoid exposure of samples containing montelukast to light.]

**IDENTIFICATION**

- A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Ultraviolet-Visible Spectroscopy:** 197U  
**Diluent:** [Methanol](#) and [water](#) (3:1)  
**Standard solution:** 0.026 mg/mL of [USP Montelukast Dicyclohexylamine RS](#) in *Diluent*  
**Sample solution:** Nominally 0.02 mg/mL of montelukast prepared as follows. Transfer one Tablet equivalent to 10 mg of montelukast to a suitable volumetric flask, add 25% of the flask volume of [water](#), and let stand for 5–10 min until the Tablet has disintegrated. Add 60% of the flask volume of [methanol](#), shake well, and sonicate for 70 min with occasional shaking. Cool to room temperature, dilute with [methanol](#) to volume, and mix well. Centrifuge a portion of the resulting solution to obtain a clear solution.  
**Wavelength range:** 210–400 nm  
**Acceptance criteria:** The *Sample solution* exhibits maxima only at the same wavelengths as the *Standard solution*.
- B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

**ASSAY**

- PROCEDURE**  
**Diluent:** [Methanol](#) and [water](#) (3:1)  
**Solution A:** 0.2% (v/v) [Trifluoroacetic acid](#) in [water](#)  
**Solution B:** [Methanol](#) and [acetonitrile](#) (3:2)  
**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	48	52
5	45	55
12	45	55
22	25	75
23	25	75
25	48	52
30	48	52

- Standard solution:** 0.52 mg/mL of [USP Montelukast Dicyclohexylamine RS](#) in *Diluent*
- System suitability solution:** Transfer 10 mL of the *Standard solution* to a clear 10-mL volumetric flask, add 4 µL of [hydrogen peroxide](#), and mix well. Expose the flask for at least 4 h to ambient light or 10 min to a 4 klx cool white light. [NOTE—Montelukast is partially converted to the *cis*-isomer under these conditions.]
- Sensitivity solution:** 0.52 µg/mL of [USP Montelukast Dicyclohexylamine RS](#) in *Diluent* from the *Standard solution*
- Sample solution:** Nominally 0.4 mg/mL of montelukast prepared as follows. Transfer a number of Tablets equivalent to 100 mg of montelukast to a suitable volumetric flask, add 70% of the flask volume of *Diluent*, and sonicate for 30 min. Shake for 30 min on a platform shaker. Dilute with *Diluent* to volume and stir for 30 min. Pass a portion through a suitable filter of 0.45-µm pore size, discarding the first mL of filtrate. Use the filtrate.

**Chromatographic system**(See [Chromatography \(621\)](#), [System Suitability](#).)**Mode:** LC**Detector:** UV 255 nm**Columns****Guard:** 3.0-mm × 4-mm; packing [L11](#)**Analytical:** 4.6-mm × 10-cm; 3-μm packing [L11](#)**Column temperature:** 50°**Flow rate:** 1.5 mL/min**Injection volume:** 15 μL**Run time:** 2 times the retention time of montelukast**System suitability****Samples:** *Standard solution*, *System suitability solution*, and *Sensitivity solution*[NOTE—The relative retention times for the *cis*-isomer and montelukast are about 0.92 and 1.0, respectively.]**Suitability requirements****Resolution:** NLT 1.5 between the *cis*-isomer and montelukast, *System suitability solution***Relative standard deviation:** NMT 2% for five injections, *Standard solution***Signal-to-noise ratio:** NLT 10, *Sensitivity solution***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

 $r_U$  = peak response from the *Sample solution* $r_S$  = peak response from the *Standard solution* $C_S$  = concentration of [USP Montelukast Dicyclohexylamine RS](#) in the *Standard solution* (mg/mL) $C_U$  = nominal concentration of montelukast in the *Sample solution* (mg/mL) $M_{r1}$  = molecular weight of montelukast, 586.18 $M_{r2}$  = molecular weight of montelukast dicyclohexylamine, 767.50**Acceptance criteria:** 92.5%–107.5%**PERFORMANCE TESTS**• [DISSOLUTION \(711\)](#)**Test 1****Medium:** 0.5% (w/v) [Sodium dodecyl sulfate](#) in [water](#); 900 mL. Do not deaerate.**Apparatus 2:** 50 rpm**Time:** 20 min**Solution A:** 0.2% (v/v) [Trifluoroacetic acid](#) in [water](#)**Solution B:** 0.2% (v/v) [Trifluoroacetic acid](#) in [acetonitrile](#)**Mobile phase:** *Solution A* and *Solution B* (1:1)**Standard stock solution:** 0.35 mg/mL of [USP Montelukast Dicyclohexylamine RS](#) in [methanol](#) (equivalent to 0.27 mg/mL of montelukast)**Standard solution:** ( $L/900$ ) mg/mL of montelukast in *Medium* from the *Standard stock solution*, where  $L$  is the label claim in mg/Tablet of montelukast**Sample solution:** Pass a portion of the solution under test through a suitable filter or centrifuge to obtain a clear solution.**Chromatographic system**(See [Chromatography \(621\)](#), [System Suitability](#).)**Mode:** LC**Detector:** UV 389 nm**Column:** 3.0-mm × 10-cm; 5-μm packing [L11](#)**Column temperature:** 50°**Flow rate:** 0.9 mL/min**Injection volume:** 20 μL**Run time:** 1.5 times the retention time of montelukast**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT 2%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of montelukast in the *Standard solution* (mg/mL)

$V$  = volume of *Medium*, 900 mL

$L$  = label claim (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) is dissolved.

**Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

**Medium:** 0.5% (w/v) [Sodium dodecyl sulfate](#) in [water](#); 900 mL

**Apparatus 2:** 50 rpm

**Time:** 45 min

**Solution A:** 0.07 g/L of [monobasic sodium phosphate](#)

**Solution B:** [Acetonitrile](#)

**Mobile phase:** *Solution A* and *Solution B* (45:55). Add 1.33 mL/L of [triethylamine](#) and adjust with [phosphoric acid](#) to a pH of 6.7.

**Standard stock solution:** 0.1 mg/mL of montelukast from montelukast sodium hydrate prepared as follows. Transfer a suitable amount of montelukast sodium hydrate to a suitable volumetric flask. Dissolve in 5% of the flask volume of [methanol](#) and dilute with *Medium* to volume. Determine the water content of montelukast sodium hydrate at the time of use.

**Standard solution:** 0.01 mg/mL of montelukast in *Medium* from the *Standard stock solution*

**Sample solution:** Centrifuge a portion of the solution under test.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 225 nm

**Column:** 4.6-mm × 5-cm; 1.8-μm packing [L1](#)

**Column temperature:** 35°

**Flow rate:** 1 mL/min

**Injection volume:** 100 μL

**Run time:** 1.5 times the retention time of montelukast

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of montelukast in the *Standard solution* (mg/mL)

$V$  = volume of *Medium*, 900 mL

$L$  = label claim (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) is dissolved.

**Test 3:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 3*.

**Medium:** 0.5% (w/v) [Sodium dodecyl sulfate](#) in [water](#); 900 mL

**Apparatus 2:** 50 rpm

**Time:** 30 min

**Solution A:** [Acetonitrile](#) and [water](#) (80:20)

**Solution B:** 3% [Trifluoroacetic acid](#) in *Solution A* prepared as follows. Transfer 3 mL of [trifluoroacetic acid](#) to a 100-mL volumetric flask and dilute with *Solution A* to volume.

**Mobile phase:** [Acetonitrile](#), [water](#), and *Solution B* (75: 25: 0.05).

**Standard solution:** ( $L/900$ ) mg/mL of montelukast in *Medium* from montelukast sodium hydrate, where  $L$  is the label claim in mg/Tablet of montelukast. Determine the water content of montelukast sodium hydrate at the time of use.

**Sample solution:** Pass a portion of the solution under test through a suitable filter to obtain a clear solution.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 346 nm

**Column:** 4.6-mm × 10-cm; 3-μm packing [L1](#)

**Flow rate:** 1.5 mL/min

**Injection volume:** 25 μL

**Run time:** NLT 1.5 times the retention time of montelukast

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of montelukast in the *Standard solution* (mg/mL)

$V$  = volume of *Medium*, 900 mL

$L$  = label claim (mg/Tablet)

**Tolerances:** NLT 80% ( $Q$ ) of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) is dissolved.

#### Change to read:

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): ▲Meet the requirements▲ (CN 1-Aug-2023)

#### Procedure for content uniformity

**Solution A, Solution B, Mobile phase, and System suitability:** Proceed as directed in *Dissolution Test 1*.

**Diluent:** [Methanol](#) and [water](#) (3:1)

**Standard solution:** 0.052 mg/mL of [USP Montelukast Dicyclohexylamine RS](#) in *Diluent*

**Sample solution:** Nominally 0.04 mg/mL of montelukast prepared as follows. Transfer one Tablet equivalent to 10 mg of montelukast to a suitable volumetric flask, add 25% of the flask volume of [water](#), and let stand for 5–10 min until the Tablet has disintegrated. Add 60% of the flask volume of [methanol](#), shake well, and sonicate for 70 min with occasional shaking. Cool to room temperature, dilute with [methanol](#) to volume, and mix well. Pass a portion of the resulting solution through a suitable filter or centrifuge to obtain a clear solution.

**Chromatographic system:** Proceed as directed in *Dissolution Test 1*, except use an *Injection volume* of 10 μL.

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of montelukast ( $C_{35}H_{36}ClNO_3S$ ) in the Tablet taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Montelukast Dicyclohexylamine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of montelukast in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of montelukast, 586.18

$M_{r2}$  = molecular weight of montelukast dicyclohexylamine, 767.50

▲ (CN 1-Aug-2023)

**IMPURITIES****• ORGANIC IMPURITIES**

**Diluent, Solution A, Solution B, Mobile phase, Standard solution, System suitability solution, Sensitivity solution, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of any individual degradation product in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/F) \times 100$$

$r_U$  = peak response of any individual degradation product from the *Sample solution*

$r_S$  = peak response of montelukast from the *Standard solution*

$C_S$  = concentration of [USP Montelukast Dicyclohexylamine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of montelukast in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of montelukast, 586.18

$M_{r2}$  = molecular weight of montelukast dicyclohexylamine, 767.50

$F$  = relative response factor (see [Table 2](#))

**Acceptance criteria:** See [Table 2](#). Disregard any peak with an area less than that of the *Sensitivity solution*.

**Table 2**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Sulfoxide impurity <sup>a,b</sup>	0.45	1.0	2.0
Montelukast ketone impurity <sup>c</sup>	0.71	1.7	0.2
cis-Isomer <sup>d</sup>	0.92	1.0	0.3
Montelukast	1.0	—	—
Methylketone impurity <sup>e,f</sup>	1.04	—	—
Michael adduct 1 <sup>g,e</sup>	1.16	—	—
Michael adduct 2 <sup>h,e</sup>	1.18	—	—
Methylstyrene impurity <sup>i,e</sup>	1.55	—	—
Any other individual degradation product	—	1.0	0.2
Total impurities	—	—	3.0

<sup>a</sup> These two impurities are not resolved by the method and need to be integrated together to determine conformance.

<sup>b</sup> [1-[[[1-[3-[(E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfinyl]methyl]cyclopropyl]acetic acid.

<sup>c</sup> (E)-1-[3-[2-(7-Chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propan-1-one.

<sup>d</sup> [1-[[[(1R)-1-[3-[(Z)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid.

- <sup>e</sup> This is a process impurity and is included in the table for identification only. This impurity is controlled in the drug substance. It is not to be reported for the drug product and should not be included in the total impurities.
- <sup>f</sup> [1-[[[(1*R*)-3-(2-Acetylphenyl)-1-[3-[(*E*)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid.
- <sup>g</sup> 1-[[[(1*R*)-1-[3-[(1*R*)-1-[[[1-(Carboxymethyl)cyclopropyl]methyl]sulfanyl]-2-(7-chloroquinolin-2-yl)ethyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid.
- <sup>h</sup> 1-[[[(1*R*)-1-[3-[(1*S*)-1-[[[1-(Carboxymethyl)cyclopropyl]methyl]sulfanyl]-2-(7-chloroquinolin-2-yl)ethyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid.
- <sup>i</sup> [1-[[[(1*R*)-1-[3-[(*E*)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-methylethenyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light. Store at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11).**

[USP Montelukast Dicyclohexylamine RS](#)       $C_{35}H_{36}ClNO_3S \cdot C_{12}H_{23}N$       767.50

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MONTELUKAST SODIUM TABLETS	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:  
Pharmacopeial Forum: Volume No. PF 40(5)

Current DocID: **GUID-0FF697DF-A945-4F14-997C-EFD080C792EF\_4\_en-US**  
DOI: [https://doi.org/10.31003/USPNF\\_M54777\\_04\\_01](https://doi.org/10.31003/USPNF_M54777_04_01)  
DOI ref: [5bha5](#)